Murray Esler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Murray Esler has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
Gavin Lambert
Human Neurotransmitter Research Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
15 shared publications- Markus P. Schlaich
Dobney Hypertension Centre, University of Western Australia, Perth, Western Australia, Australia
15 shared publications - Elisabeth Annie Lambert
Swinburne University of Technology
13 shared publications David Kaye
Human Neurotransmitter Research Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia
10 shared publications- Gavin W. Lambert
Iverson Health Innovation Research Institute, Swinburne University of Technology, Hawthorn, VIC 3122, Australia
10 shared publications - Garry Lr Jennings
The University of Sydney Charles Perkins Centre, Sydney, New South Wales, Australia
9 shared publications
Latest Publications
- Open Access
- 19 January 2026
- Published by Academia.edu in Academia Medicine and Health
- Vol. 3 (1)
Gravity-dependent blood pressure rise in essential hypertension: mechanism of orthostatic hypertension
Background: Orthostatic hypertension (oHTN)—a paradoxical increase in blood pressure upon standing—remains understudied despite its association with increased cardiovascular risk in individuals with essential hypertension. The role of low-pressure cardiopulmonary reflexes in mediating this condition is not well understood. Objective: This study aimed to determine whether greater reductions in central blood volume (CBV) from venous pooling during orthostatic stress, increased sensitivity of the low pressure cardiopulmonary reflex to this blood pooling, or both, contribute to the pathophysiology of oHTN. Materials and Methods: Twenty-three patients with untreated essential hypertension underwent graded head-up tilt testing (15°, 25°, 35°) to evaluate CBV changes using indocyanine green dye dilution. Simultaneous measurements of arterial pressure, total peripheral resistance index (TPRI), and plasma renin activity were recorded. Patients in the top quintile of diastolic blood pressure (DBP) response during tilt were categorized as having oHTN. Results: Patients with oHTN exhibited significantly greater CBV reduction (−28.6% vs. −19.5% at 35°; p < 0.05), steeper increases in TPRI (46.2% vs. 11.9%; p < 0.01), and greater increase in plasma renin activity (2.23 vs. 0.77 ng/ml/h; p < 0.05) compared to non-oHTN patients. A direct correlation between fall in CBV and increase in TPR was observed, suggesting a volume-sensitive reflex mechanism, but gain of the low pressure cardiopulmonary reflex (ΔTPR/ΔCBV) was normal, not contributing to the exaggerated hemodynamic changes. Conclusions: oHTN is characterized by excessive vasoconstriction and neurohumoral activation in response to exaggerated central hypovolemia during orthostatic stress. These findings support a pivotal role for the volume-sensitive reflex—rather than the arterial baroreflex—in the development of oHTN and identify potential therapeutic targets.
- 19 January 2026
- Published by Academia.edu in Academia Medicine and Health
- Vol. 3 (1)
Open AccessGravity-dependent blood pressure rise in essential hypertension: mechanism of orthostatic hypertension
Background: Orthostatic hypertension (oHTN)—a paradoxical increase in blood pressure upon standing—remains understudied despite its association with increased cardiovascular risk in individuals with essential hypertension. The role of low-pressure cardiopulmonary reflexes in mediating this condition is not well understood. Objective: This study aimed to determine whether greater reductions in central blood volume (CBV) from venous pooling during orthostatic stress, increased sensitivity of the low pressure cardiopulmonary reflex to this blood pooling, or both, contribute to the pathophysiology of oHTN. Materials and Methods: Twenty-three patients with untreated essential hypertension underwent graded head-up tilt testing (15°, 25°, 35°) to evaluate CBV changes using indocyanine green dye dilution. Simultaneous measurements of arterial pressure, total peripheral resistance index (TPRI), and plasma renin activity were recorded. Patients in the top quintile of diastolic blood pressure (DBP) response during tilt were categorized as having oHTN. Results: Patients with oHTN exhibited significantly greater CBV reduction (−28.6% vs. −19.5% at 35°; p < 0.05), steeper increases in TPRI (46.2% vs. 11.9%; p < 0.01), and greater increase in plasma renin activity (2.23 vs. 0.77 ng/ml/h; p < 0.05) compared to non-oHTN patients. A direct correlation between fall in CBV and increase in TPR was observed, suggesting a volume-sensitive reflex mechanism, but gain of the low pressure cardiopulmonary reflex (ΔTPR/ΔCBV) was normal, not contributing to the exaggerated hemodynamic changes. Conclusions: oHTN is characterized by excessive vasoconstriction and neurohumoral activation in response to exaggerated central hypovolemia during orthostatic stress. These findings support a pivotal role for the volume-sensitive reflex—rather than the arterial baroreflex—in the development of oHTN and identify potential therapeutic targets.
- Open Access
- 1 July 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (7) , e110-e113
In Memoriam: Stevo Julius, MD, ScD
- 1 July 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (7) , e110-e113
Open AccessIn Memoriam: Stevo Julius, MD, ScD
- 1 June 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (6) , e63-e70
Long-Term Blood Pressure Reductions Following Catheter-Based Renal Denervation: A Systematic Review and Meta-Analysis
BACKGROUND: Renal denervation is a recognized adjunct therapy for hypertension with clinically significant blood pressure (BP)-lowering effects. Long-term follow-up data are critical to ascertain durability of the effect and safety. Aside from the 36-month follow-up data available from randomized control trials, recent cohort analyses extended follow-up out to 10 years. We sought to analyze study-level data and quantify the ambulatory BP reduction of renal denervation across contemporary randomized sham-controlled trials and available long-term follow-up data up to 10 years from observational studies. METHODS: A systematic review was performed with data from 4 observational studies with follow-up out to 10 years and 2 randomized controlled trials meeting search and inclusion criteria with follow-up data out to 36 months. Study-level data were extracted and compared statistically. RESULTS: In 2 contemporary randomized controlled trials with 36-month follow-up, an average sham-adjusted ambulatory systolic BP reduction of −12.7±4.5 mm Hg from baseline was observed ( P =0.05). Likewise, a −14.8±3.4 mm Hg ambulatory systolic BP reduction was found across observational studies with a mean long-term follow-up of 7.7±2.8 years (range, 3.5–9.4 years; P =0.0051). The observed reduction in estimated glomerular filtration rate across the long-term follow-up was in line with the predicted age-related decline. Antihypertensive drug burden was similar at baseline and follow-up. CONCLUSIONS: Renal denervation is associated with a significant and clinically meaningful reduction in ambulatory systolic BP in both contemporary randomized sham-controlled trials up to 36 months and observational cohort studies up to 10 years without adverse consequences on renal function.
- 1 June 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (6) , e63-e70
Long-Term Blood Pressure Reductions Following Catheter-Based Renal Denervation: A Systematic Review and Meta-Analysis
BACKGROUND: Renal denervation is a recognized adjunct therapy for hypertension with clinically significant blood pressure (BP)-lowering effects. Long-term follow-up data are critical to ascertain durability of the effect and safety. Aside from the 36-month follow-up data available from randomized control trials, recent cohort analyses extended follow-up out to 10 years. We sought to analyze study-level data and quantify the ambulatory BP reduction of renal denervation across contemporary randomized sham-controlled trials and available long-term follow-up data up to 10 years from observational studies. METHODS: A systematic review was performed with data from 4 observational studies with follow-up out to 10 years and 2 randomized controlled trials meeting search and inclusion criteria with follow-up data out to 36 months. Study-level data were extracted and compared statistically. RESULTS: In 2 contemporary randomized controlled trials with 36-month follow-up, an average sham-adjusted ambulatory systolic BP reduction of −12.7±4.5 mm Hg from baseline was observed ( P =0.05). Likewise, a −14.8±3.4 mm Hg ambulatory systolic BP reduction was found across observational studies with a mean long-term follow-up of 7.7±2.8 years (range, 3.5–9.4 years; P =0.0051). The observed reduction in estimated glomerular filtration rate across the long-term follow-up was in line with the predicted age-related decline. Antihypertensive drug burden was similar at baseline and follow-up. CONCLUSIONS: Renal denervation is associated with a significant and clinically meaningful reduction in ambulatory systolic BP in both contemporary randomized sham-controlled trials up to 36 months and observational cohort studies up to 10 years without adverse consequences on renal function.
- Open Access
- 7 May 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 72, 102626
Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trial
- 7 May 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 72, 102626
Open AccessEfficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trial
- Open Access
- 1 April 2024
- Published by Wolters Kluwer Health in Cardiology Plus
- Vol. 9 (2) , 71-73
Recent international milestones for renal denervation treatment of hypertension: achievements in China
- 1 April 2024
- Published by Wolters Kluwer Health in Cardiology Plus
- Vol. 9 (2) , 71-73
Open AccessRecent international milestones for renal denervation treatment of hypertension: achievements in China
- Open Access
- 14 September 2023
- Published by Springer Nature in Clinical Autonomic Research
- Vol. 33 (6) , 613-615
Coffee drinking then and now: research continues to better understand this ubiquitous beverage
- 14 September 2023
- Published by Springer Nature in Clinical Autonomic Research
- Vol. 33 (6) , 613-615
Open AccessCoffee drinking then and now: research continues to better understand this ubiquitous beverage
- Open Access
- 18 May 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (3) , 100799
C-13 | Cost-Effectiveness of Renal Denervation for Uncontrolled Hypertension in the Presence of Antihypertensive Drugs: An Analysis for the U.S. Based on 6-Month Primary Results from the SPYRAL HTN-ON MED Randomized Trial
- 18 May 2023
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 2 (3) , 100799
Open AccessC-13 | Cost-Effectiveness of Renal Denervation for Uncontrolled Hypertension in the Presence of Antihypertensive Drugs: An Analysis for the U.S. Based on 6-Month Primary Results from the SPYRAL HTN-ON MED Randomized Trial
- Top Cited Papers
- 1 April 2023
- Published by Wolters Kluwer Health in Hypertension
- Vol. 80 (4) , 811-819
Catheter-Based Renal Denervation: 9-Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients With Resistant Hypertension
Background: Recent sham-controlled randomized clinical trials have confirmed the safety and efficacy of catheter-based renal denervation (RDN). Long-term safety and efficacy data beyond 3 years are scarce. Here, we report on outcomes after RDN in a cohort of patients with resistant hypertension with an average of ≈9-year follow-up (FU). Methods: We recruited patients with resistant hypertension who were previously enrolled in various RDN trials applying radiofrequency energy for blood pressure (BP) lowering. All participants had baseline assessments before RDN and repeat assessment at long-term FU including medical history, automated office and ambulatory BP measurement, and routine blood and urine tests. We analyzed changes between baseline and long-term FU. Results: A total of 66 participants (mean±SD, 70.0±10.3 years; 76.3% men) completed long-term FU investigations with a mean of 8.8±1.2 years post-procedure. Compared with baseline, ambulatory systolic BP was reduced by −12.1±21.6 (from 145.2 to 133.1) mm Hg ( P P P =0.0052). Renal function assessed by estimated glomerular filtration rate fell within the expected age-associated rate of decline from 71.1 to 61.2 mL/min per 1.73 m 2 . Time above target was reduced significantly from 75.0±25.9% at baseline to 47.3±30.3% at long-term FU ( P <0.0001). Conclusions: RDN results in a significant and robust reduction in both office and ambulatory systolic and diastolic BP at ≈9-year FU after catheter-based RDN on less medication and without evidence of adverse consequences on renal function.
- 1 April 2023
- Published by Wolters Kluwer Health in Hypertension
- Vol. 80 (4) , 811-819
Top Cited PapersCatheter-Based Renal Denervation: 9-Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients With Resistant Hypertension
Background: Recent sham-controlled randomized clinical trials have confirmed the safety and efficacy of catheter-based renal denervation (RDN). Long-term safety and efficacy data beyond 3 years are scarce. Here, we report on outcomes after RDN in a cohort of patients with resistant hypertension with an average of ≈9-year follow-up (FU). Methods: We recruited patients with resistant hypertension who were previously enrolled in various RDN trials applying radiofrequency energy for blood pressure (BP) lowering. All participants had baseline assessments before RDN and repeat assessment at long-term FU including medical history, automated office and ambulatory BP measurement, and routine blood and urine tests. We analyzed changes between baseline and long-term FU. Results: A total of 66 participants (mean±SD, 70.0±10.3 years; 76.3% men) completed long-term FU investigations with a mean of 8.8±1.2 years post-procedure. Compared with baseline, ambulatory systolic BP was reduced by −12.1±21.6 (from 145.2 to 133.1) mm Hg ( P P P =0.0052). Renal function assessed by estimated glomerular filtration rate fell within the expected age-associated rate of decline from 71.1 to 61.2 mL/min per 1.73 m 2 . Time above target was reduced significantly from 75.0±25.9% at baseline to 47.3±30.3% at long-term FU ( P <0.0001). Conclusions: RDN results in a significant and robust reduction in both office and ambulatory systolic and diastolic BP at ≈9-year FU after catheter-based RDN on less medication and without evidence of adverse consequences on renal function.
- Open Access
- 26 August 2022
- Published by Taylor & Francis in Blood Pressure
- Vol. 31 (1) , 210-224
Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified
Beta-blockers have solid documentation in preventing cardiovascular complications in the treatment of hypertension; atenolol, metoprolol, oxprenolol and propranolol demonstrate proven cardiovascular prevention in hypertension mega-trials. Hypertension is characterised by activation of the sympathetic nervous system from early to late phases, which makes beta-blockers an appropriate treatment seen from a pathophysiological viewpoint, especially in patients with an elevated heart rate. Beta-blockers represent a heterogenous class of drugs with regard to both pharmacodynamic and pharmacokinetic properties. This position is manifest by reference to another clinical context, beta-blocker treatment of heart failure, where unequivocally there is no class effect (no similar benefit from all beta-blockers); there are good and less good beta-blockers for heart failure. Analogous differences in beta-blocker efficacy is also likely in hypertension. Beta-blockers are widely used for the treatment of diseases comorbid with hypertension, in approximately 50 different concomitant medical conditions that are frequent in patients with hypertension, leading to many de facto beta-blocker first choices in clinical practice. Thus, beta-blockers should be regarded as relevant first choices for hypertension in clinical practice, particularly if characterised by a long half-life, highly selective beta-1 blocking activity and no intrinsic agonist properties.
- 26 August 2022
- Published by Taylor & Francis in Blood Pressure
- Vol. 31 (1) , 210-224
Open AccessDiverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified
Beta-blockers have solid documentation in preventing cardiovascular complications in the treatment of hypertension; atenolol, metoprolol, oxprenolol and propranolol demonstrate proven cardiovascular prevention in hypertension mega-trials. Hypertension is characterised by activation of the sympathetic nervous system from early to late phases, which makes beta-blockers an appropriate treatment seen from a pathophysiological viewpoint, especially in patients with an elevated heart rate. Beta-blockers represent a heterogenous class of drugs with regard to both pharmacodynamic and pharmacokinetic properties. This position is manifest by reference to another clinical context, beta-blocker treatment of heart failure, where unequivocally there is no class effect (no similar benefit from all beta-blockers); there are good and less good beta-blockers for heart failure. Analogous differences in beta-blocker efficacy is also likely in hypertension. Beta-blockers are widely used for the treatment of diseases comorbid with hypertension, in approximately 50 different concomitant medical conditions that are frequent in patients with hypertension, leading to many de facto beta-blocker first choices in clinical practice. Thus, beta-blockers should be regarded as relevant first choices for hypertension in clinical practice, particularly if characterised by a long half-life, highly selective beta-1 blocking activity and no intrinsic agonist properties.
- Open Access
- 2 June 2022
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 818012
Measurement of Noradrenaline and Serotonin Metabolites With Internal Jugular Vein Sampling: An Indicator of Brain Monoamine Turnover in Depressive Illness and Panic Disorder
In research spanning three decades we have estimated brain monoamine turnover (approximately equating with synthesis rate) with sampling from the internal jugular veins and measurement of trans-cerebral plasma monoamine metabolite concentration gradients. Here we report indices of brain noradrenaline and serotonin turnover in patients with major depressive illness (MDD) and panic disorder (PD). Brain noradrenaline turnover was assessed from the combined flux into the internal jugular veins of the metabolites dihydroxyphenylglycol (DHPG) and 3-hydroxy-4-methoxyphenylglycol (MHPG), and brain serotonin turnover from the overflow of the primary metabolite, 5-hydroxyindole acetic acid (5HIAA). Comparison was made with matched healthy research participants. In both MD and PD the estimate of brain noradrenaline turnover provided by metabolite overflow was unremarkable. In contrast, in both patient groups the estimate of brain serotonin turnover provided by 5HIAA overflow was increased 3–4-fold (P < 0.01). This neurotransmitter abnormality was normalized in MDD and PD in clinical remission, during selective serotonin reuptake blocker (SSRI) dosing. We cannot be sure if the brain serotonergic abnormality we find in MDD and PD is causal or a correlate. Measurements in PD were not made during a panic attack. The increased estimated serotonin turnover here may possibly be a substrate for panic attacks; serotonergic raphe nuclei participate in anxiety responses in experimental animals. It is puzzling that the findings were identical in MDD and PD, although it may be pertinent that these psychiatric diagnoses are commonly comorbid. It is unlikely that activation of brain serotonergic neurons is driving the sympathetic nervous activation present, which contributes to cardiovascular risk, persistent sympathetic activation in MDD and episodic activation in PD during panic attacks. We have previously demonstrated that the mechanism of activation of human central sympathetic outflow in other contexts (hypertension, heart failure) is activation of noradrenergic brainstem neurons projecting to the hypothalamus and amygdala.
- 2 June 2022
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 818012
Open AccessMeasurement of Noradrenaline and Serotonin Metabolites With Internal Jugular Vein Sampling: An Indicator of Brain Monoamine Turnover in Depressive Illness and Panic Disorder
In research spanning three decades we have estimated brain monoamine turnover (approximately equating with synthesis rate) with sampling from the internal jugular veins and measurement of trans-cerebral plasma monoamine metabolite concentration gradients. Here we report indices of brain noradrenaline and serotonin turnover in patients with major depressive illness (MDD) and panic disorder (PD). Brain noradrenaline turnover was assessed from the combined flux into the internal jugular veins of the metabolites dihydroxyphenylglycol (DHPG) and 3-hydroxy-4-methoxyphenylglycol (MHPG), and brain serotonin turnover from the overflow of the primary metabolite, 5-hydroxyindole acetic acid (5HIAA). Comparison was made with matched healthy research participants. In both MD and PD the estimate of brain noradrenaline turnover provided by metabolite overflow was unremarkable. In contrast, in both patient groups the estimate of brain serotonin turnover provided by 5HIAA overflow was increased 3–4-fold (P < 0.01). This neurotransmitter abnormality was normalized in MDD and PD in clinical remission, during selective serotonin reuptake blocker (SSRI) dosing. We cannot be sure if the brain serotonergic abnormality we find in MDD and PD is causal or a correlate. Measurements in PD were not made during a panic attack. The increased estimated serotonin turnover here may possibly be a substrate for panic attacks; serotonergic raphe nuclei participate in anxiety responses in experimental animals. It is puzzling that the findings were identical in MDD and PD, although it may be pertinent that these psychiatric diagnoses are commonly comorbid. It is unlikely that activation of brain serotonergic neurons is driving the sympathetic nervous activation present, which contributes to cardiovascular risk, persistent sympathetic activation in MDD and episodic activation in PD during panic attacks. We have previously demonstrated that the mechanism of activation of human central sympathetic outflow in other contexts (hypertension, heart failure) is activation of noradrenergic brainstem neurons projecting to the hypothalamus and amygdala.